Ftse Mib
33.311,37
1,23%
DAX
18.131,97
0,32%
S&P 500
5.479,68
0,12%
NASDAQ
17.849,52
-0,04%
Bitcoin
64.489,61
-3,00%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Phio Pharmaceuticals Corporation (PHIO) Phio Pharmaceuticals Corporation (PHIO) Notizie

PHIO

Phio Pharmaceuticals (PHIO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PHIO
DataOraFonteTitoloSimboloCompagnia
28/05/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
20/05/202423:03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
20/05/202422:59Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202415:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202415:00GlobeNewswire Inc.Phio Pharmaceuticals Secures New InvestorNASDAQ:PHIOPhio Pharmaceuticals Corporation
16/05/202414:00GlobeNewswire Inc.Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
15/05/202419:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation StudyNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/05/202423:25GlobeNewswire Inc.Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/05/202423:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202423:04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202423:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202423:00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PHIOPhio Pharmaceuticals Corporation
30/04/202413:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)NASDAQ:PHIOPhio Pharmaceuticals Corporation
22/04/202419:10GlobeNewswire Inc.Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsNASDAQ:PHIOPhio Pharmaceuticals Corporation
16/04/202413:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
11/04/202413:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)NASDAQ:PHIOPhio Pharmaceuticals Corporation
03/04/202413:30GlobeNewswire Inc.National Spotlight Features Phio’s Innovative RNAi Technology PlatformNASDAQ:PHIOPhio Pharmaceuticals Corporation
02/04/202413:30GlobeNewswire Inc.Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
21/03/202412:30GlobeNewswire Inc.Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
13/03/202419:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/03/202416:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/03/202401:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/02/202416:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PHIOPhio Pharmaceuticals Corporation
31/01/202414:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
28/12/202315:13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
28/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHIOPhio Pharmaceuticals Corporation
19/12/202322:52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
19/12/202319:07Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
07/12/202314:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/11/202322:30GlobeNewswire Inc.Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PHIO

La tua Cronologia

TSX
5845
Zenhoren
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network